Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -46.39% is 38% below its 5-year average of -33.71%, near the low end of its 5-year range (-46.39%–-10.60%).
23.07% below its 12-month average of -37.70%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.28%.
RETURN ON ASSETS (ROA)
-46.39%
RETURN ON ASSETS (ROA) AVG TTM
-37.70%
RETURN ON ASSETS (ROA) AVG 3Y
-40.46%
RETURN ON ASSETS (ROA) AVG 5Y
-33.71%
RETURN ON ASSETS (ROA) AVG 10Y
-36.21%
RETURN ON ASSETS (ROA) AVG 15Y
-37.48%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.07%
CURRENT VS 3Y AVG
-14.65%
CURRENT VS 5Y AVG
-37.61%
CURRENT VS 10Y AVG
-28.13%
CURRENT VS 15Y AVG
-23.77%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
-45.24%
vs the sector median at left
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.43B
Return on Assets (ROA)
-46.39%
TTM Avg
-37.70%
3Y Avg
-40.46%
5Y Avg
-33.71%
Market Cap
$1.43B
Return on Assets (ROA)
-25.13%
TTM Avg
-5.66%
3Y Avg
-57.10%
5Y Avg
-57.10%
Market Cap
$1.44B
Return on Assets (ROA)
-4.89%
TTM Avg
-0.43%
3Y Avg
-0.87%
5Y Avg
-1.37%
Market Cap
$1.42B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.44B
Return on Assets (ROA)
14.98%
TTM Avg
6.07%
3Y Avg
5.42%
5Y Avg
6.72%
Market Cap
$1.41B
Return on Assets (ROA)
3.12%
TTM Avg
3.19%
3Y Avg
2.54%
5Y Avg
2.30%
Market Cap
$1.41B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.45B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Assets (ROA)
-31.81%
TTM Avg
-43.72%
3Y Avg
-70.87%
5Y Avg
-63.61%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.43B | -46.39% | -37.70% | -40.46% | -33.71% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | -25.13% | -5.66% | -57.10% | -57.10% |
| Certara, Inc. (CERT)vs › | $1.44B | -4.89% | -0.43% | -0.87% | -1.37% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 61.75% | -16.82% | -22.73% | -17.45% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 14.98% | 6.07% | 5.42% | 6.72% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 3.12% | 3.19% | 2.54% | 2.30% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | -21.52% | -21.52% | -21.52% | -21.52% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -31.81% | -43.72% | -70.87% | -63.61% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | -29.88% | -23.31% | -25.68% | -25.68% |
ROA
-46.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.53% |
| 2024-12-31 | -37.86% |
| 2023-12-31 | -40.69% |
| 2022-12-31 | -45.77% |
| 2021-12-31 | -29.82% |
| 2020-12-31 | -10.60% |
| 2019-12-31 | -35.47% |
| 2018-12-31 | -27.46% |
| 2017-12-31 | -61.57% |
| 2016-12-31 | -45.48% |
| 2015-12-31 | -26.02% |
| 2014-12-31 | -30.21% |
| 2013-12-31 | -58.79% |
| 2012-12-31 | -18.49% |
| 2011-12-31 | -56.47% |
